Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Huntington Disease l: Introduction

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comment on Residual neuromuscular blockade following electroconvulsive therapy.

Anaesthesia and intensive care·2026

Same author

Relapse Prevention After Successful ECT for Depression: The Role of Lithium and Continuation/Maintenance ECT.

The American journal of psychiatry·2026

Same author

Variability in Real-World Electroconvulsive Therapy (ECT) Practice: Is Perfection the Enemy of the Good?

The journal of ECT·2026

Same author

Electroconvulsive therapy (ECT) reduces suicidal behavior and suicide deaths: Response to Naismith et al.

Psychological medicine·2025

Same author

Electroconvulsive Therapy (ECT) for Postpartum Psychosis: Treatment for a Medical Emergency.

The American journal of psychiatry·2025

Same author

Ketamine versus ECT for major depression: flawed evidence base.

The lancet. Psychiatry·2025

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

ECT for Parkinson's disease.

Dennis Popeo, Charles H Kellner

Medical Hypotheses

|August 8, 2009

Summary

Electroconvulsive therapy (ECT) offers significant benefits for Parkinson's disease (PD) motor and psychiatric symptoms by enhancing dopamine neurotransmission. Despite its efficacy, stigma has limited its clinical adoption for PD treatment.

Area of Science:

Neurology
Psychiatry

Background:

Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting millions globally, primarily managed with dopaminergic pharmacotherapy.
Neurosurgical interventions like deep brain stimulation (DBS) are options for refractory PD cases.
Electroconvulsive therapy (ECT) demonstrates consistent benefits for PD symptoms but lacks clinical acceptance.

Discussion:

ECT positively impacts both core motor deficits and psychiatric comorbidities in Parkinson's disease.
The therapeutic mechanism of ECT in PD is hypothesized to involve enhanced dopaminergic neurotransmission and receptor sensitivity.
Observed benefits of ECT in PD patients can be variable in duration, with maintenance ECT potentially prolonging therapeutic effects.

Key Insights:

Review of literature indicates ECT's efficacy in managing Parkinson's disease motor and psychiatric symptoms.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons

Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons

Published on: July 7, 2023

Related Experiment Videos

Last Updated: Jun 21, 2026

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons

Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons

Published on: July 7, 2023

ECT may offer a viable treatment alternative, particularly for PD patients with co-occurring depression.

The persistent stigma associated with ECT is a significant barrier to its clinical application in Parkinson's disease management.

Outlook:

Further research and education are needed to overcome the stigma surrounding ECT for Parkinson's disease.
ECT could represent a valuable therapeutic option for select Parkinson's disease patients, including those with comorbid depression.
Exploring novel delivery methods or patient selection criteria may enhance ECT's acceptance and utility in PD treatment.